September 16, 2024
2 min read
Save

Long-term data support pembrolizumab as ‘a standard of care’ in advanced melanoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • More patients who received pembrolizumab than ipilimumab survived at least 10 years.
  • A second course of pembrolizumab benefited some patients.

Pembrolizumab significantly extended OS at 10 years compared with ipilimumab for patients with advanced melanoma, according to study results presented at ESMO Congress.

A second course of pembrolizumab (Keytruda, Merck) exhibited anti-tumor activity in some patients, results showed.

10-year OS rates infographic
Data derived from Robert C, et al. Abstract LBA44. Presented at: European Society for Medical Oncology Congress; Sept. 13-17, 2024; Barcelona, Spain.

“These results confirm that pembrolizumab provides long-term benefit for advanced melanoma, supporting it as a standard of care in this setting,” Caroline Robert, MD, PhD, head of dermatology at Gustave Roussy Cancer Campus and co-director of the melanoma research unit at INSERM 981 Paris-Sud University, and colleagues wrote.

Background and methods

The randomized phase 3 KEYNOTE-006 included 834 patients with unresectable stage III or stage IV melanoma who had received no more than one prior line of treatment, excluding CTLA-4 and PD-1 inhibitors.

Researchers randomly assigned 556 participants to receive 10 mg/kg pembrolizumab every 2 weeks or every 3 weeks for up to 2 years. The other 278 patients received 3 mg/kg ipilimumab (Yervoy, Bristol Myers Squibb) every 3 weeks for four cycles.

Results of KEYNOTE-006 showed pembrolizumab exhibited “superior efficacy” compared with ipilimumab, researchers wrote.

After KEYNOTE-006, patients had the option to transition to the KEYNOTE-587 extension study. Eligible patients could receive a second course of pembrolizumab — for a maximum 1 year — as part of either KEYNOTE-006 or KEYNOTE-587.

After KEYNOTE-006, 211 patients — including 159 who previously received pembrolizumab — transferred into the into KEYNOTE-587.

For patients who transitioned, median time from entry in KEYNOTE-006 to data cut-off in KEYNOTE-587 was 123.7 months (range, 122-127.3).

OS served as the primary endpoint in KEYNOTE-587. Modified PFS served as a secondary endpoint.

Results

Results showed longer median PFS (32.7 months vs. 15.9 months; HR = 0.71; 95% CI, 0.6-0.85) and a higher 10-year OS rate (34% vs. 23.6%) with pembrolizumab than ipilimumab.

Among the 103 patients who completed at least 94 weeks of pembrolizumab, median OS after week 94 had not been reached. The 8-year OS in this group was 80.8%.

The OS benefit with pembrolizumab persisted across subgroups, including those determined to have poor prognostic features.

Researchers reported longer median modified PFS (9.4 months vs. 3.8 months; HR = 0.64; 95% CI, 0.54-0.75) with pembrolizumab.

Among the 16 patients who received a second course of pembrolizumab, median modified PFS from the start of the second course was 51.8 months (95% CI, 11 to not reached), with a 6-year modified PFS rate of 49.2%.